Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against  from cystic fibrosis patients in biofilm by unknown
Lutz et al. BMC Microbiology 2012, 12:196
http://www.biomedcentral.com/1471-2180/12/196RESEARCH ARTICLE Open AccessMacrolides decrease the minimal inhibitory
concentration of anti-pseudomonal agents
against Pseudomonas aeruginosa from cystic
fibrosis patients in biofilm
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Background: Biofilm production is an important mechanism for bacterial survival and its association with
antimicrobial resistance represents a challenge for the patient treatment. In this study we evaluated the in vitro
action of macrolides in combination with anti-pseudomonal agents on biofilm-grown Pseudomonas aeruginosa
recovered from cystic fibrosis (CF) patients.
Results: A total of 64 isolates were analysed. The biofilm inhibitory concentration (BIC) results were consistently
higher than those obtained by the conventional method, minimal inhibitory concentration, (MIC) for most anti-
pseudomonal agents tested (ceftazidime: P= 0.001, tobramycin: P= 0.001, imipenem: P< 0.001, meropenem:
P= 0.005). When macrolides were associated with the anti-pseudomonal agents, the BIC values were reduced
significantly for ceftazidime (P < 0.001) and tobramycin (P < 0.001), regardless the concentration of macrolides.
Strong inhibitory quotient was observed when azithromycin at 8 mg/L was associated with all anti-pseudomonal
agents tested in biofilm conditions.
Conclusions: P. aeruginosa from CF patients within biofilms are highly resistant to antibiotics but macrolides
proved to augment the in vitro activity of anti-pseudomonal agents.
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The main cause of morbidity and mortality in cystic fibro-
sis (CF) is chronic lung disease caused by a vicious cycle
of infection and inflammation which leads to progressive
deterioration of pulmonary function, respiratory failure,
and death [1]. Pseudomonas aeruginosa is the main bac-
teria associated with pulmonary disease in CF. In vivo and
in vitro evidence suggests that P. aeruginosa produce bio-
film within the airways of chronic CF pulmonary infection
patients,[2-5] which is a protective barrier around the bac-
terial cells and limits exposure to oxidative radicals, anti-
biotics, and phagocytes [6]. Bacterial biofilms play a
relevant role in persistent infections, which are rarely era-
dicated with antimicrobial therapy [7].* Correspondence: albarth@hcpa.ufrgs.br
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reproduction in any medium, provided the orDespite the evidence of P. aeruginosa grown in the air-
ways of CF patients in biofilm form, the susceptibility pro-
file of the bacterium is usually evaluated, in vitro, in the
planktonic state. However, the planktonic susceptibility
profile may not represent the actual susceptibility of the
bacteria [7]. To overcome the potential shortfalls of trad-
itional (planktonic) microbiological methods to evaluate
susceptibility, biofilm models have been proposed to ac-
cess susceptibility of P. aeruginosa in vitro [8].
Macrolide antibiotics are being evaluated for the treat-
ment of chronic lung inflammatory diseases, including dif-
fuse panbronchiolitis, CF, chronic obstructive pulmonary
disease, and asthma. Although macrolides have no anti-
microbial activity against P. aeruginosa at therapeutic con-
centrations, there is great interest in the evaluation of
treatments of CF patients with these antibiotics, at least as
complementary therapy [9-11]. Anti-inflammatory activity. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clinical trials [12-17]. Macrolides have also proved to
present potential effects on inhibition of bacterial biofilm
with reduction of bacterial virulence factor when used in
sub-inhibitory concentrations [18]. In the present study,
we evaluated the in vitro action of macrolides in combin-
ation with anti-pseudomonal agents on biofilm-grown
P. aeruginosa recovered from CF patients.
Results
The MIC50 and MIC90 (mg/L) for the 64 isolates were as
follows: ceftazidime (CAZ) 2 and 16; ciprofloxacin (CIP)
0.5 and 16; tobramycin (TOB) 2 and 64; imipenem
(IPM) 1 and 16; meropenem (MEM) 0.5 and 4; respect-
ively. BIC50 and BIC90 (mg/L) for all isolates were as fol-
lows: CAZ 8 and 256; CIP 1 and 64; TOB 4 and 64; IPM
16 and 256; MEM 2 and 32, respectively. There was a
statistical significant difference between MIC and BIC
values of isolates for all antibiotics tested (Table 1).
The number of “non-susceptible” (“Resistant” - “R” -
plus “Intermediate” - “I”) isolates according to MIC and
BIC for each antibiotic was as follows: CAZ 9/64 (14.1%)
and 24/64 (37.5%); CIP 19/64 (29.7%) and 23/64 (36%);
TOB 13/64 (20.4%) and 30/64 (46.8%); IPM 15/64
(23.4%) and 44/64 (68.8%); MEM 6/64 (9.4%) and 18/64
(28.1%), respectively. There was a statistical significant dif-
ference between the susceptibility category of isolates for all
antibiotics tested, except for CIP (CAZ: P=0.001, CIP:
P=0.234, TOB: P=0.001, IPM: P<0.001, MEM: P=0.005).
The macrolide MIC values were tested for all isolates.
Both azithromycin (AZM) (range 32 - 4096) and clari-
thromycin (CLR) (range 128 - 4096) presented a median
MIC of 512 mg/L. MIC50 and MIC90 (mg/L) for all iso-
lates were 512 and 1024 for AZM; 512 and 4096 for
CLR, respectively.
The non-suscetible isolates according to BIC results
were included in the macrolide combination assay
(MCA) with CAZ (28 isolates – median BIC 128 mg/L),
CIP (23 isolates – median BIC 16 mg/L), TOB (30 iso-
lates – median BIC 16 mg/L), IPM (44 isolates – median





No. of isolates inhibited by diff
≤0.5 1 2 4 8
CAZ 0.5-256/ 0.5-256 3/5 16/10 22/11 8/1 6/3
CIP 0.5-128/ 0.5-256 42/31 3/10 7/4 2/2 1/3
TOB 0.5-256/ 0.5-256 9/4 17/6 18/13 7/11 1/7
IPM 0.5-128/ 0.5-256 21/8 17/1 6/2 5/9 7/6
MEM 0.5-64/ 0.5-256 38/21 7/0 7/18 6/7 4/1
Detailed legend: CAZ - ceftazidime, CIP - ciprofloxacin, TOB - tobramycin, IPM - imip
P – statistical significance (< 0.05), MIC – minimal inhibitory concentration, BIC – bio8 mg/L). When 2 mg/L of CLR was associated with the
anti-pseudomonal agents, the median BIC values were
significantly reduced for CAZ (P< 0.001) and TOB (P<
0.001), but not for CIP (P=1.000), IPM (P=1.000), and
MEM (P=1.000). At higher CLR concentration (8 mg/L),
BIC values significantly reduced when associated with
CAZ (P< 0.001), but not when associated with CIP
(P= 1.000), TOB (P= 0.108), IPM (P=1.000), and MEM
(P= 1.000). In the presence of 2 mg/L of AZM in combin-
ation with the anti-pseudomonal agents, the median BIC
values were reduced significantly for CAZ (P=0.001), CIP
(P= 0.009), and TOB (P= 0.001), but not when associated
with IPM (P=1.000) and MEM (P=1.000), while the pres-
ence of 8 mg/L of AZM in association with all antibiotics
showed reduction in median BIC values for all antibiotics
tested (CAZ: P< 0.001, CIP: P< 0.001, TOB: P< 0.001,
IPM: P< 0.001, MEM: P< 0.001) (Figure 1).
CLR at 2 mg/L presented strong inhibitory quotient
(IQ) when associated with TOB (66.7% of isolates) and
CAZ (57.1% of isolates). CLR at 8 mg/L presented strong
IQ when associated with CAZ (57.1% of isolates). AZM
at 2 mg/L presented a strong IQ when associated with
CAZ (50% of isolates), CIP (43.5% of isolates), and TOB
(86.7% of isolates). Moreover, 8 mg/L of AZM in com-
bination with all anti-pseudomonal agents tested pre-
sented the highest proportion of isolates with strong IQ
for all antibiotics tested: CAZ (75%); CIP (73.9%); TOB
(70%); IPM (88.6%); and MEM (61.1%) (Figure 2).
A total of 19 (29.7%) isolates presented the mucoid
phenotype, but no statistical significant differences in
the susceptibility profile of mucoid and non-mucoid
isolates were found for the antibiotics tested in the
different conditions performed in this study (MIC,
BIC and MCA).
The repeatability of the assays demonstrated a coeffi-
cient of variation (CV) of MIC and BIC for CAZ, CIP,
IPM, MEM, and TOB of 10.21 and 9.45, 7.09 and 8.46,
14.74 and 2.13, 7.70 and 3.94, 10.01 and 8.51, respect-
ively. When macrolides were associated, the highest CV
was 20.12% for CAZ with 8 mg/L of CLR and the lowest
was 0% for TOB with 2 and 8 mg/L of CLR.eruginosa (n = 64) in planktonic and in biofilm conditions







value16 32 64 128 ≥256
3/6 2/4 3/4 0/4 1/12 2/8 16/256 <0.001
5/3 3/4 0/4 1/1 0/2 0.5/1 16/64 0.016
1/10 1/4 3/4 0/1 7/4 2/4 64/64 0.008
6/11 1/6 0/5 1/5 0/11 1/16 16/256 <0.001
0 0/0 1/2 1/0 0/1 0/5 0.5/2 4/32 <0.001
enem, MEM - meropenem,
film inhibitory concentration.
Figure 1 Azithromycin and clarithromycin action on biofilm inhibitory concentration (BIC) of non-susceptible P. aeruginosa isolates
combined with anti-pseudomonal agents. Detailed legend: CAZ - ceftazidime, CIP - ciprofloxacin, TOB - tobramycin, IPM - imipenem, MEM -
meropenem, CLR - clarithromycin, AZM – azithromycin. Results are expressed as median of BIC. Solid lines represent association with AZM;
dashed lines represent association with CLR.
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Bacteria in biofilm are more prone to resist treatment with
antibiotics and to evade the action of immune system cells.
The present study observed a significant difference be-
tween MIC in planktonic and in biofilm growth conditions.
BIC values were considerably higher than the conventional
MIC values for all anti-pseudomonal antibiotics tested in
our study as also found by Moskowitz and collaborators
[19]. MEM proved to be the most active antibiotic regard-
less the growth condition, CAZ proved to be the secondmost active antibiotic in planktonic conditions of growth,
whereas CIP was the second most active antibiotic in
biofilm conditions. In vitro studies have indicated that CIP
is one of the most active agents against bacterial biofilm of
S. aureus and P. aeruginosa. This is possibly related to the
fluoroquinolones ability to penetrate into biofilms killing
non-growing bacteria [20-22]. As expected, all isolates
were resistant to AZM and CLR.
The principal finding of our study was that non-
susceptible P. aeruginosa exposed to macrolides at sub-
Figure 2 Inhibitory Quotient (IQ) of combinations of macrolide antibiotics to anti-pseudomonal agents against P. aeruginosa isolates.
Detailed legend: CAZ 2AZM – ceftazidime with 2 mg/L of azithromycin, CAZ 8AZM - ceftazidime with 8 mg/L of azithromycin, CAZ 2CLR -
ceftazidime with 2 mg/L of clarithromycin, CAZ 8CLR - ceftazidime with 8 mg/L of clarithromycin, CIP 2AZM – ciprofloxacin with 2 mg/L of
azithromycin, CIP 8AZM - ciprofloxacin with 8 mg/L of azithromycin, CIP 2CLR - ciprofloxacin with 2 mg/L of clarithromycin, CIP 8CLR -
ciprofloxacin with 8 mg/L of clarithromycin, TOB 2AZM – tobramycin with 2 mg/L of azithromycin, TOB 8AZM - tobramycin with 8 mg/L of
azithromycin, TOB 2CLR - tobramycin with 2 mg/L of clarithromycin, TOB 8CLR - with 8 mg/L of clarithromycin, IPM 2AZM – imipenem with
2 mg/L of azithromycin, IPM 8AZM - imipenem with 8 mg/L of azithromycin, IPM 2CLR - imipenem with 2 mg/L of clarithromycin, IPM 8CLR -
imipenem with 8 mg/L of clarithromycin, MEM 2AZM – meropenem with 2 mg/L of azithromycin, MEM 8AZM – meropenem with 8 mg/L of
azithromycin, MEM 2CLR – meropenem with 2 mg/L of clarithromycin, MEM 8CLR – meropenem with 8 mg/L of clarithromycin. STRONG IQ
(Black bar) means that there was a reduction in biofilm inhibitory concentration (BIC) when macrolides combination was tested and the isolates
changed its profile from “Resistant” to “Susceptible”; WEAK IQ (Grey bar) means that there was a reduction in BIC value when the isolate profile
changed from “Resistant” to “Intermediate”.
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of anti-pseudomonal agents (CAZ, CIP, IPM, MEM,
and TOB) in biofilm conditions. It is of note that in
many associations we found a strong IQ between anti-
pseudomonal agents and macrolides. The impact of
tobramycin/clarithromycin and ceftazidime/clarithromy-
cin co-administration on P. aeruginosa biofilms was also
observed in studies of Tré-Hardy and collaborators
[23,24]. Other study showed that the biofilm was
strongly affected by the presence of clarithromycin, and,
in its presence, amikacin MIC lower than those obtained
in the absence of clarithromycin [25].
In our study, co-administration of AZM at 8 mg/L pre-
sented considerable impact when associated with all anti-
pseudomonal agents tested (CAZ, CIP, IPM, MEM, and
TOB) on P. aeruginosa biofilms from CF patients. Al-
though AZM has no bactericidal effect on P. aeruginosa,
it was shown that AZM retards the formation of bio-
films and blocks the bacterial quorum sensing involved
in the production of biofilms [26-28]. The use of AZM
to treat chronic infections of P. aeruginosa in the lungs
of CF patients has been gaining favour due to the
improved outcome of CF patients treated with this anti-
biotic [29,30].
Synergistic and additive activities were noted when
AZM and CLR were paired with conventional anti-
microbial agents for P. aeruginosa strains in the study of
Saiman and collaborators. Overall, combinations were
more active against CF isolates than against non-CF iso-
lates and more active against mucoid strains than againstnon-mucoid strains [31]. However, in our study no sig-
nificant difference in the macrolides combination assay
was observed when we compared mucoid with non-
mucoid P. aeruginosa clinical isolates.
Interpretative criteria of susceptibility are not standar-
dized for the combination assay in biofilm conditions
and this is the main limitation of our study. Therefore,
one must be aware that the biofilm susceptibility testing
and the macrolide combination assay proposed in our
study need further clinical validation for applying it in
microbiology laboratories.
Conclusions
In conclusion, P. aeruginosa clinical isolates from CF
patients within biofilms are highly resistant to antibiotics
and macrolides may be useful as adjunctive therapy as




A total of 64 P. aeruginosa isolates were collected from
the sputum of 34 (20 male and 14 female) CF patients
attending at the Cystic Fibrosis Centre in Hospital de
Clínicas de Porto Alegre, Brazil, from December 2005 to
July 2008. The median age of patients was 13 years
(range 2 - 30) and the majority of patients presented
positive sputum culture for P. aeruginosa for at least
5 years. In most children cases, the sputum was obtained
only after respiratory physiotherapy. Sputum samples
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methods [32]. Isolates of P. aeruginosa obtained from
the sputum culture were stored at −80°C. P. aeruginosa
ATCC 27853 was used as quality control for the anti-
pseudomonal agents, S. aureus ATCC 25923 was used as
quality control for the macrolides agents, and PA01 was
used as reference of biofilm-forming bacteria.
Susceptibility tests
Antimicrobial agents
Stock solution of antibiotics were prepared following the
instructions of the manufacturer (Sigma-AldrichW Co, St
Louis, USA) and stored at −80°C until use. Working
solutions were prepared in cation-adjusted Mueller-Hin-
ton broth (CAMHB) (Becton Dickinson, Sparks, MD) at
512 mg/L for CAZ, CIP, TOB, IPM, and MEM. AZM
and CLR working solutions were prepared at 8192 mg/L.
From these working solutions serial twofold dilutions
were prepared in CAMHB and distributed in a 96-well
microtiter plate.
Minimal inhibitory concentration (MIC) and biofilm
inhibitory concentration (BIC)
MIC values were determined by broth microdilution
using the twofold dilution method according to the Clin-
ical and Laboratory Standards Institute (CLSI) guidelines
[33]. The antibiotic concentrations tested ranged from
0.5 to 256 mg/L for the anti-pseudomonal antibiotics
CAZ, CIP, TOB, IPM, and MEM; and from 2 to
4096 mg/L for the macrolides AZM and CLR.
BIC values were determined as previously described
[19]. Prior to testing, the organisms were subcultured in
trypticase soy broth with 5% KNO3 and incubated over-
night after retrieval from −80°C. Bacteria were re-
subcultured in MacConkey agar (bioMèrieuxW, France)
and incubated overnight. A bacterial suspension in
CAMHB containing 5% KNO3 was prepared with an in-
oculum density equivalent to 0.5 McFarland (Densimat,
bioMèrieuxW). Afterwards, 100 μL were inoculated into
all but the negative control of a flat-bottom 96-well
microtiter plate. Plates were covered with lids presenting
96 pegs in which the biofilms could build up, followed
by incubation at 37°C for 20 h. Peg lids were rinsed
three times with sterile saline to remove non-binding
cells, placed onto other 96-well flat-bottom microplates
containing a range of antibiotic concentrations and incu-
bated for 18 to 20 h at 37°C. Pegs carrying control bio-
films were submerged in antibiotic-free medium. After
antibiotic incubation, peg lids were again rinsed three
times in sterile saline and incubated in fresh CAMHB in
a new microplate and centrifugated at 805 X g for
20 min. The peg lid was discarded and replaced by a
standard lid. The optical density (OD) at 650 nm was
measured on a microtiter plate colorimeter before andafter incubation at 37°C for 6 h (OD650 at 6 h minus
OD650 at 0 h). Biofilm formation was defined as a mean
OD650 difference ≥ 0.05 for the biofilm control. The
BIC values were defined as the lowest concentration
without growth. CLSI criteria [34] were used to classify
the isolates as ¨Susceptible¨ (“S”), ¨Intermediate¨ (“I”)
or ¨Resistant¨ (“R”).
Macrolide combination assay (MCA) and inhibitory quotient
(IQ)
Only isolates with a BIC value in “R” or "I” classification
according to CLSI interpretative criteria [34] for CAZ,
CIP, TOB, IPM, and MEM were used in the MCA and IQ.
MCA was performed in a 96-well microplate containing
CAZ, CIP, TOB, IPM, or MEM in twofold dilutions in
addition to macrolides at sub-inhibitory concentrations
[35]. With the purpose to assign activity of AZM and CLR
in combination with the antibiotics and to better evaluate
susceptibility changing category, we established an inhi-
bitory quotient (IQ). IQ is the quotient of the maximum
antibiotic serum concentration and the BIC value of
each antibiotic in combination with the macrolide. IQ
categorization for CAZ, CIP, TOB, IPM, and MEM to
evaluate the activity of macrolides in different concentra-
tions against resistant P. aeruginosa isolates was as follows:
strong IQ (IQ ≥ 2, except for CIP, whose IQ was ≥ 1), weak
IQ (IQ=0.5), or non-inhibition (IQ ≤ 0.5). Strong IQ
means that there was a reduction in BIC when macrolide
combination was tested and the isolates changed their pro-
file from “R” to “S”; weak IQ means that there was a re-
duction in the BIC value when the isolate profile changed
from “R” to “I”; and non-inhibition means no change in
the bacteria antibiotic susceptibility profile [36].
All assays were performed four times. Mean values of the
four repetitions, standard deviations, and CV were calcu-
lated and the mean value was considered the value which
was then used to categorize the isolates as “R”, “I” or “S”.
The susceptibility profile of mucoid and non-mucoid
isolates was evaluated under the different conditions
performed in this study (MIC, BIC and MCA).
Statistical analysis
The Wilcoxon signed ranks test was used for statistical
analysis of quantitative values of MIC and BIC.
McNemar-Bowker test was used to evaluate the categor-
ies of the results obtained (“S”, “I” and “R”) by the stand-
ard technique and the technique in biofilm. P < 0.05
indicated statistical significance.
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